Progress in the development of nucleic acid therapeutics

0Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Abnormal gene expression is a hallmark of many diseases. Gene-specific down-regulation of aberrant genes could be useful therapeutically and potentially less toxic than conventional therapies due its specificity. Over the years, many strategies have been proposed for silencing gene expression in a gene-specific manner. Three major approaches are antisense oligonucleotides (AS-ONs), ribozymes/DNAzymes, and RNA interference (RNAi). In this brief review, we will discuss the successes and shortcomings of these three gene-silencing methods, and the approaches being taken to improve the effectiveness of antisense molecules. We will also provide an overview of some of the clinical applications of antisense therapy. © 2006 Springer-Verlag Berlin Heidelberg.

Cite

CITATION STYLE

APA

Kalota, A., Dondeti, V. R., & Gewirtz, A. M. (2006). Progress in the development of nucleic acid therapeutics. Handbook of Experimental Pharmacology, 173, 173–196. https://doi.org/10.1007/3-540-27262-3_9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free